Innoviva Revenue 2006-2020 | INVA

Innoviva revenue from 2006 to 2020. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Innoviva Annual Revenue
(Millions of US $)
2019 $261
2018 $261
2017 $217
2016 $134
2015 $54
2014 $8
2013 $5
2012 $6
2011 $25
2010 $24
2009 $24
2008 $23
2007 $22
2006 $20
2005 $12
Innoviva Quarterly Revenue
(Millions of US $)
2020-03-31 $79
2019-12-31 $76
2019-09-30 $66
2019-06-30 $64
2019-03-31 $55
2018-12-31 $80
2018-09-30 $62
2018-06-30 $67
2018-03-31 $52
2017-12-31 $70
2017-09-30 $49
2017-06-30 $59
2017-03-31 $40
2016-12-31 $44
2016-09-30 $33
2016-06-30 $32
2016-03-31 $24
2015-12-31 $23
2015-09-30 $14
2015-06-30 $11
2015-03-31 $7
2014-12-31 $7
2014-09-30 $1
2014-06-30 $1
2014-03-31 $-1
2013-12-31 $1
2013-09-30 $0
2013-06-30 $1
2013-03-31 $1
2012-12-31 $6
2012-09-30 $1
2012-06-30 $1
2012-03-31 $127
2011-12-31 $5
2011-09-30 $6
2011-06-30 $6
2011-03-31 $6
2010-12-31 $7
2010-09-30 $5
2010-06-30 $6
2010-03-31 $6
2009-12-31 $4
2009-09-30 $6
2009-06-30 $5
2009-03-31 $10
2008-12-31 $6
2008-09-30 $6
2008-06-30 $6
2008-03-31 $6
2007-12-31 $6
2007-09-30 $6
2007-06-30 $5
2007-03-31 $5
2006-12-31 $5
2006-09-30 $6
2006-06-30 $5
2006-03-31 $4
2005-12-31 $3
2005-09-30 $3
2005-06-30 $3
2005-03-31 $3
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $1.415B $0.261B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $391.896B 16.75
Roche Holding AG (RHHBY) Switzerland $296.882B 0.00
Pfizer (PFE) United States $212.139B 13.17
Merck (MRK) United States $203.745B 14.76
Novartis AG (NVS) Switzerland $200.372B 15.64
Novo Nordisk (NVO) Denmark $155.276B 25.86
Eli Lilly (LLY) United States $146.289B 23.68
AstraZeneca (AZN) United Kingdom $143.291B 29.51
AbbVie (ABBV) United States $136.850B 10.05
Bristol-Myers Squibb (BMY) United States $135.128B 11.29
Sanofi (SNY) $122.978B 14.23
GlaxoSmithKline (GSK) United Kingdom $105.157B 12.55
Bayer (BAYRY) Germany $63.786B 9.10
H Lundbeck (HLUYY) Denmark $7.631B 13.26